



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: HIV-1 gp120 Monoclonal Antibody (F425 B4a1)

Catalog Number: 7625

Lot Number: 098117

Release Category: C

Provided: 100 µg at 1.5 mg/ml in PBS. Purified from tissue culture supernatant by protein G chromatography. The antibody is stable at this concentration. If a less concentrated stock is needed, dilute the material no further than 1 mg/ml.

Description: Purified from tissue culture supernatant by protein G chromatography.

Host: EBV-transformed B cell x HMMA2.5 TG/O heteromyeloma.

Titer: Use at 10-20 µg/ml for flow cytometry.

Special Characteristics: Reacts with the V3 loop of gp120; neutralizes primary isolates.

Recommended Storage: Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.

Contributor: Dr. Marshall Posner and Dr. Lisa Cavacini.

Isotype: IgG₁, lambda.

References: Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. *Virology* 2007;**364**:441-53.

Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, Wilson IA. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. *J Mol Biol* 2008;**377**:66-76.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp120 Monoclonal Antibody (F425 B4a1) from Dr. Marshall Posner and Dr. Lisa Cavacini."

Requests from commercial organizations should be directed to Michael Legregni, JD, Technology Ventures Office, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, BR2, Boston, MA 02215. Email: mlegregn@bidmc.harvard.edu.

Last Updated

October 13, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.